Characterization of the TLR9-Activating Potential of LNA-Modified Antisense Oligonucleotides.

LNA TLR9 antisense methylation oligonucleotide

Journal

Nucleic acid therapeutics
ISSN: 2159-3345
Titre abrégé: Nucleic Acid Ther
Pays: United States
ID NLM: 101562758

Informations de publication

Date de publication:
17 Jul 2024
Historique:
medline: 17 7 2024
pubmed: 17 7 2024
entrez: 17 7 2024
Statut: aheadofprint

Résumé

Early characterization of the immunostimulatory potential of therapeutic antisense oligonucleotides (ASOs) is crucial. At present, little is known about the toll-like receptor 9 (TLR9)-mediated immunostimulatory potential of third-generation locked nucleic acid (LNA)-modified ASOs. In this study, we have systematically investigated the TLR9-activating potential of LNA-modified oligonucleotides using different mouse and human cell culture systems. Although it has been reported that LNA modifications as well as cytosine methylation of 5'-cytosine-phosphate-guanine-3' (CpG) motifs can reduce TLR9 stimulation by phosphorothioate (PTO)-modified oligonucleotides, we identified CpG-containing LNA gapmers with substantial TLR9-stimulatory activity. We further identified immunostimulatory LNA gapmers without CpG motifs. Unexpectedly, methylation of cytosines only within the CpG motif did not necessarily reduce but could even increase TLR9 activation. In contrast, systematic methylation of all cytosines reduced or even abrogated TLR9 activation in most cases. Context dependently, the introduction of LNA-modifications into the flanks could either increase or decrease TLR9 stimulation. Overall, our results indicate that TLR9-dependent immunostimulatory potential is an individual feature of an oligonucleotide and needs to be investigated on a case-by-case basis.

Identifiants

pubmed: 39018509
doi: 10.1089/nat.2024.0013
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Irene Riera-Tur (I)

Secarna Pharmaceuticals GmbH & Co. KG, Planegg, Germany.

Julia Hinterdobler (J)

Secarna Pharmaceuticals GmbH & Co. KG, Planegg, Germany.

André Maaske (A)

Secarna Pharmaceuticals GmbH & Co. KG, Planegg, Germany.

Anne Sadewasser (A)

Secarna Pharmaceuticals GmbH & Co. KG, Planegg, Germany.

Monika Schell (M)

Secarna Pharmaceuticals GmbH & Co. KG, Planegg, Germany.

Janani Sekar (J)

Secarna Pharmaceuticals GmbH & Co. KG, Planegg, Germany.

Sven Michel (S)

Secarna Pharmaceuticals GmbH & Co. KG, Planegg, Germany.

Richard Klar (R)

Secarna Pharmaceuticals GmbH & Co. KG, Planegg, Germany.

Frank Jaschinski (F)

Secarna Pharmaceuticals GmbH & Co. KG, Planegg, Germany.

Classifications MeSH